Evaluate CJC-1295 with DAC for-sale listings by identity, peptide content, lot-specific testing, handling evidence, pricing context, and approval status.
CJC-1295 with DAC for sale typically refers to a research peptide sold online for laboratory use, not a prescription drug approved for human consumption. It is a modified growth hormone-releasing hormone (GHRH) analog that includes a Drug Affinity Complex (DAC) to extend its half-life. Before buying, researchers should verify vendor purity, legal status, and intended use restrictions.
A CJC-1295 with DAC for sale listing should be assessed as a claim about a specific research material, not evidence that it is suitable for performance or medical use.
What Is CJC-1295 with DAC?
The approximately 6–8-day figure comes from healthy human adults given the DAC compound: Teichman and colleagues estimated a half-life of 5.8–8.1 days after a single subcutaneous administration. It is not an animal-only estimate or a value established for every product labeled CJC-1295.
The material marketed as CJC-1295 no DAC or Mod GRF (1-29) lacks the albumin-binding modification and is distinct from the DAC compound studied in the cited human trials. FDA’s assessment cautions against transferring the DAC pharmacological profile to non-DAC forms; it does not establish a universal 30-minute human half-life or a daily regimen for all such products.
After a single administration in that study, mean GH increased about 2–10-fold for at least six days, while mean IGF-1 increased about 1.5–3-fold for nine to eleven days. These are group biomarker findings, not proof of muscle gain, fat loss, better sleep, or long-term safety.
How CJC-1295 with DAC Compares to Other Options
Ipamorelin acts through the ghrelin receptor pathway, whereas CJC-1295 acts through the GHRH receptor pathway. Different mechanisms do not establish a safe combination dose, compatibility in one vial, or superior sleep, recovery, or body composition. The cited DAC trials did not validate the online CJC-1295/ipamorelin schedules.
Sermorelin is a separate GHRH peptide with its own historical clinical products and evidence. Its past approvals do not mean that CJC-1295, a retail vial, or a proposed blend is approved.
The table identifies distinct materials and evidence boundaries; it does not recommend a supplier, product, or personal protocol.
| Material | Relevant distinction | Evidence context | Approval implication |
|---|---|---|---|
| CJC-1295 DAC | Albumin-binding GHRH analog | Short human PK and hormone studies | No FDA-approved CJC-1295 indication |
| No DAC / Mod GRF (1-29) | Distinct non-DAC material | Cannot inherit DAC trial results | No CJC-1295 approval established |
| Ipamorelin | Ghrelin receptor pathway | Different compound; combination not established here | Not approved by association |
| Sermorelin | Separate GHRH peptide | Historical evidence requires exact product/indication | Not a CJC-1295 approval |
What to Check When Buying CJC-1295 with DAC
A lot-matched report can document the sample tested, method, date, and result. It does not prove every vial has the same content, that a supplier-submitted sample was independently purchased, or that the material is sterile or clinically safe. Acceptance criteria should follow the laboratory’s intended assay, rather than a universal 98% purity threshold.
- Third-party testing: Look for recent COAs with batch numbers.
- Content and identity: distinguish peptide identity, HPLC purity, net peptide content, and any assay-specific acceptance criteria; no single percentage validates every use.
- Handling: request supported storage and shipping conditions for the exact formulation rather than assuming frozen transport is always necessary.
- Labeling: a research-use statement is not proof of product quality or permission for human use.
- Quantity: verify the nominal vial amount and the basis of the content claim.
CJC-1295 has no FDA-approved human indication. A “research use only” label does not itself authorize human treatment or settle whether a particular sale, import, or possession is lawful. Product claims, intended use, compounding requirements, and jurisdiction matter; an ordinary retail research vial is not an approved prescription medicine.
A missing or mismatched report is a documentation gap. It does not establish how common counterfeit or underfilled vials are in the entire market.
No dated supplier quotations are provided here, so a current 5 mg price range cannot be verified. Compare exact products, currency, date, shipping, taxes, and content documentation instead of relying on an unsourced market range.
Dosage and Research Context
The 2006 randomized, placebo-controlled trials followed healthy adults for 28 or 49 days. Single-dose cohorts received 30, 60, 125, or 250 mcg/kg; the repeat-dose study used two or three administrations at weekly or biweekly intervals. These were monitored research protocols, not an approved personal dosing schedule.
Do not label fixed weekly community amounts as animal-to-human dose conversions or as the regimen established by those human trials.
Different mechanisms do not establish a clinically validated stack or a single-vial mixing protocol.
How to Store and Handle CJC-1295 with DAC
Storage temperature and use-by time depend on the peptide formulation, solvent, concentration, container, and validated stability data. There is no universal “refrigerate for four weeks” or “freeze at −20°C” rule for every retail CJC-1295 vial. CDC’s opened multidose-vial guidance is not evidence that a newly mixed peptide remains chemically stable for 28 days. A listing and a CJC-1295 with DAC dosage discussion answer different questions: an offered vial amount does not establish a clinically suitable regimen. A 5 mg DAC listing or vial description specifies offered mass, which still requires identity and amount verification rather than inference from the label.
Correct handling preserves the conditions of a validated method; it cannot make an unverified peptide identity or content claim accurate.
Safety and Legal Considerations
The short human studies reported injection-site reactions, flushing or warmth, headache, and gastrointestinal symptoms. FDA also identifies serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and notes limited clinical data and impurity/immunogenicity concerns. Neither a tolerable first exposure nor a normal blood test establishes long-term safety.
Specific short-study adverse events should be distinguished from unquantified claims about fluid retention, numbness, or glucose changes in personal logs.
Clinical suitability, compounding requirements, and drug marketing rules must be assessed separately. A research product is not an approved medicine simply because a clinician is consulted.
Bottom Line
For laboratory purchasing, the useful checks are exact identity, nominal versus measured content, lot-specific evidence, and validated handling. No vendor is endorsed by the fact that CJC-1295 appears in a clinical paper.
Frequently Asked Questions
Is CJC-1295 with DAC legal to buy in the US?
No FDA-approved CJC-1295 medicine is established here. Laboratory labeling is not a blanket legal exemption for human treatment, and approval, compounding, import, sale, and possession are distinct questions. A specific legal answer requires the actual product, purpose, and jurisdiction.
What is the difference between CJC-1295 with DAC and without DAC?
No. Material marketed as no DAC or Mod GRF (1-29) lacks the albumin-binding modification and is distinct from the DAC compound studied in the cited trials. The 5.8–8.1-day human DAC half-life and schedule cannot be transferred to it. DAC also did not abolish GH pulses in the cited human sampling study.
What dosage of CJC-1295 with DAC do people use?
The cited evidence does not establish a safe or effective weekly amount for personal use. Fixed 1–2 mg forum schedules are not the standard defined by the original weight-based human trials. A vial size, calculator, or subjective response cannot select a suitable dose.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.